优化生物医学研究中知情同意文件的关键信息部分:使用大型语言模型进行的一项多阶段研究
Shahana Chumki1, Caleb Smith2, Terri Ridenour1
1Office of the Vice President for Research, University of Michigan, Ann Arbor, MI, USA.
Journal of clinical and translational science
|February 16, 2026
概括
人工智能 (AI) 工具可以帮助在知情同意文件 (ICD) 中标准化关键信息部分,提高一致性和效率. 持续的人类监督对于研究伦理的准确性和监管合规性至关重要.
科学领域:
- 生物医学伦理 生物医学伦理
- 医疗保健中的人工智能
- 临床研究管理局
背景情况:
- 知情同意文件 (ICD) 缺乏标准化关键信息 (KI) 部分,使机构审查委员会 (IRB) 的审查和参与者理解变得复杂.
- 这种不一致性给研究伦理行为和监管合规性带来了挑战.
研究的目的:
- 探索GPT-4o,一个大型语言模型 (AI) 的实用性,用于生成ICD的标准化KI部分.
- 通过专家评估,评估人工智能产生的KI内容的准确性,清晰性和可用性.
主要方法:
- 开发了一个AI工具来解释和生成ICD中的KI内容.
- 多阶段评估涉及IRB主题专家,主要调查员 (PI) 和IRB审查员,评估AI输出的准确性,差异化,优先级和一致性.
- 根据专家反,实施了代改进.
主要成果:
- 人工智能生成的KI部分显示出比代改进更好的准确性和清晰度.
- 研究人员发现人工智能生成的内容与他们自己的内容相当,并表示愿意使用该工具.
- IRB审查人员指出,在描述好处和可读性方面存在优势,但强调需要改进风险描述.
结论:
- 人工智能工具显示出增强ICD KI部分起草一致性和效率的前景.
- 为了遵守法规和道德标准,需要进一步的细化和人类监督.
- 人工智能和人类专家之间的合作对于优化知情同意流程至关重要.
相关概念视频
02:07Improving Translational Accuracy
3.7K
3.7K
02:07Improving Translational Accuracy
15.1K
Base complementarity between the three base pairs of mRNA codon and the tRNA anticodon is not a failsafe mechanism. Inaccuracies can range from a single mismatch to no correct base pairing at all. The free energy difference between the correct and nearly correct base pairs can be as small as 3 kcal/ mol. With complementarity being the only proofreading step, the estimated error frequency would be one wrong amino acid in every 100 amino acids incorporated. However, error frequencies observed in...
15.1K
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
488
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
488
01:11Clinical Trials: Overview
5.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K
01:16Bioequivalence: Overview
2.0K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.0K
01:28Biopharmaceutics and Pharmacokinetics: Overview
4.3K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
4.3K